270 related articles for article (PubMed ID: 10504548)
1. Expression of Bcl-2, but not Bax, correlates with estrogen receptor status and tumor proliferation in invasive breast carcinoma.
Yang Q; Sakurai T; Jing X; Utsunomiya H; Shan L; Nakamura Y; Nakamura M; Oura S; Suzuma T; Yoshimura G; Umemura T; Kokawa Y; Kakudo K
Pathol Int; 1999 Sep; 49(9):775-80. PubMed ID: 10504548
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S
J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical status of p53, MDM2, bcl2, bax, and ER in invasive ductal breast carcinoma in Tunisian patients.
Baccouche S; Daoud J; Frikha M; Mokdad-Gargouri R; Gargouri A; Jlidi R
Ann N Y Acad Sci; 2003 Dec; 1010():752-63. PubMed ID: 15033823
[TBL] [Abstract][Full Text] [Related]
4. Immunofluorometric study of Bcl-2 and Bax expression in clinical fresh tumor samples from breast cancer patients.
Martínez-Arribas F; Núñez-Villar MJ; Lucas AR; Sánchez J; Tejerina A; Schneider J
Anticancer Res; 2003; 23(1B):565-8. PubMed ID: 12680147
[TBL] [Abstract][Full Text] [Related]
5. Bax protein expression in DCIS of the breast in relation to invasive ductal carcinoma and other molecular markers.
Rehman S; Crow J; Revell PA
Pathol Oncol Res; 2000; 6(4):256-63. PubMed ID: 11173657
[TBL] [Abstract][Full Text] [Related]
6. Bcl-2 protein expression is associated with p27 and p53 protein expressions and MIB-1 counts in breast cancer.
Tsutsui S; Yasuda K; Suzuki K; Takeuchi H; Nishizaki T; Higashi H; Era S
BMC Cancer; 2006 Jul; 6():187. PubMed ID: 16839413
[TBL] [Abstract][Full Text] [Related]
7. The extent of proliferative and apoptotic activity in intraductal and invasive ductal breast carcinomas detected by Ki-67 labeling and terminal deoxynucleotidyl transferase-mediated digoxigenin-11-dUTP nick end labeling.
Shen KL; Harn HJ; Ho LI; Yu CP; Chiu SC; Lee WH
Cancer; 1998 Jun; 82(12):2373-81. PubMed ID: 9635530
[TBL] [Abstract][Full Text] [Related]
8. Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers.
Krajewski S; Thor AD; Edgerton SM; Moore DH; Krajewska M; Reed JC
Clin Cancer Res; 1997 Feb; 3(2):199-208. PubMed ID: 9815673
[TBL] [Abstract][Full Text] [Related]
9. Expression of bax and p53 proteins in the tumorigenesis and progression of breast carcinomas.
Redondo M; Garcia J; Rodrigo I; Villar E; González C; Morell M
Tumour Biol; 2003; 24(1):23-31. PubMed ID: 12743423
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous bilateral breast carcinomas: a category with frequent coexpression of HER-2 and ER-alpha, high Ki-67 and bcl-2, and low p53.
Bassarova AV; Nesland JM; Sedloev T; Lilleby W; Hristova SL; Trifonov DY; Torlakovic E
Int J Surg Pathol; 2005 Jul; 13(3):239-46. PubMed ID: 16086078
[TBL] [Abstract][Full Text] [Related]
11. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptor expression in relation to apoptosis and the expression of cell cycle related proteins in prostate cancer.
Amirghofran Z; Monabati A; Gholijani N
Pathol Oncol Res; 2004; 10(1):37-41. PubMed ID: 15029260
[TBL] [Abstract][Full Text] [Related]
13. Apoptosis, proliferation, bax, bcl-2 and p53 status prior to and after preoperative radiochemotherapy for locally advanced rectal cancer.
Tannapfel A; Nüsslein S; Fietkau R; Katalinic A; Köckerling F; Wittekind C
Int J Radiat Oncol Biol Phys; 1998 Jun; 41(3):585-91. PubMed ID: 9635706
[TBL] [Abstract][Full Text] [Related]
14. Proliferation marker MIB-1 correlates well with proliferative activity evaluated by BrdU in breast cancer: an immunohistochemical study including correlation with PCNA, p53, c-erbB-2 and estrogen receptor status.
Moriki T; Takahashi T; Kataoka H; Hiroi M; Yamane T; Hara H
Pathol Int; 1996 Dec; 46(12):953-61. PubMed ID: 9110347
[TBL] [Abstract][Full Text] [Related]
15. Loss of bcl-2 expression in ductal carcinoma in situ of the breast relates to poor histological differentiation and to expression of p53 and c-erbB-2 proteins.
Quinn CM; Ostrowski JL; Harkins L; Rice AJ; Loney DP
Histopathology; 1998 Dec; 33(6):531-6. PubMed ID: 9870147
[TBL] [Abstract][Full Text] [Related]
16. In vivo patterns of Bcl-2 family protein expression in breast carcinomas in relation to apoptosis.
Rochaix P; Krajewski S; Reed JC; Bonnet F; Voigt JJ; Brousset P
J Pathol; 1999 Mar; 187(4):410-5. PubMed ID: 10398099
[TBL] [Abstract][Full Text] [Related]
17. Loss of Bcl-2 in invasive breast cancer is associated with high rates of cell death, but also with increased proliferative activity.
van Slooten HJ; van de Vijver MJ; van de Velde CJ; van Dierendonck JH
Br J Cancer; 1998 Mar; 77(5):789-96. PubMed ID: 9514059
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of p53 mutations, bax, and spontaneous apoptosis in maxillary sinus squamous cell carcinoma.
Bandoh N; Hayashi T; Kishibe K; Takahara M; Imada M; Nonaka S; Harabuchi Y
Cancer; 2002 Apr; 94(7):1968-80. PubMed ID: 11932899
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of clinical parameters and biological markers in patients with squamous cell carcinoma of the head and neck treated with concurrent chemoradiotherapy.
Homma A; Furuta Y; Oridate N; Nakano Y; Kohashi G; Yagi K; Nagahashi T; Yagi K; Nagahashi T; Fukuda S; Inoue K; Inuyama Y
Clin Cancer Res; 1999 Apr; 5(4):801-6. PubMed ID: 10213215
[TBL] [Abstract][Full Text] [Related]
20. Apoptosis in breast carcinoma.
González-Cámpora R; Galera Ruiz MR; Vázquez Ramírez F; Ríos Martín JJ; Fernández Santos JM; Ramos Martos MM; Gómez Pascual A
Pathol Res Pract; 2000; 196(3):167-74. PubMed ID: 10729921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
